ReviewDiscover oncology2025
Disulfidptosis mechanisms and therapeutic implications in cancer metabolic reprogramming and future perspectives.
Review in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Experimental Detection Methods and Clinical Translational Challenges of Disulfidptosis in Cancer.Cells · 2026Review
- Disulfidptosis in hepatocellular carcinoma: molecular mechanisms, therapeutic potential, and exploratory insights into chronic liver diseases.Apoptosis : an international journal on programmed cell death · 2026Review
- Constructing and investigating a disulfidptosis-associated LncRNA signature for prognostic prediction in gastric cancer.Discover oncology · 2026Article
- Role of Disulfidptosis in the Local Inflammatory Response of Atopic Dermatitis.Clinical and translational allergy · 2026Article
- Disulfidptosis as an immunometabolic rheostat in gastrointestinal cancers: tuning the balance between T Cell exhaustion and immunogenic cell death.Frontiers in cell and developmental biology · 2026Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Regulatory cell death exhibits distinctive advantages in cancer therapy. Among such mechanisms, disulfidptosis effectively inhibits tumor growth by inducing disulfide bond stress and subsequent rupture under particular conditions, thus demonstrating substantial potential for cancer treatment. Genes associated with disulfidptosis contribute to the survival and proliferation of various cancer cell types. They significantly impact the tumor microenvironment (TME) by modulating cancer's metabolic reprogramming and antioxidant response, achieving anti-tumor effects. This review explores the recently identified regulatory cell death mechanism, disulfidptosis, through an examination of its mechanisms, the relationship between relevant genes and cancer, analyses of the TME, and the prospects of emerging therapeutics, offering fresh insights for disulfidptosis research in oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.